Compare NECB & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NECB | EDIT |
|---|---|---|
| Founded | 1934 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 282.4M | 233.3M |
| IPO Year | N/A | 2016 |
| Metric | NECB | EDIT |
|---|---|---|
| Price | $21.93 | $2.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 45.1K | ★ 1.7M |
| Earning Date | 10-23-2025 | 11-10-2025 |
| Dividend Yield | ★ 4.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.21 | N/A |
| Revenue | ★ $102,569,000.00 | $46,383,000.00 |
| Revenue This Year | $1.90 | N/A |
| Revenue Next Year | $6.93 | N/A |
| P/E Ratio | $6.82 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.27 | $0.91 |
| 52 Week High | $29.74 | $4.54 |
| Indicator | NECB | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 63.88 | 42.37 |
| Support Level | $21.00 | $2.09 |
| Resistance Level | $22.19 | $2.55 |
| Average True Range (ATR) | 0.53 | 0.17 |
| MACD | 0.20 | 0.02 |
| Stochastic Oscillator | 86.43 | 51.56 |
NorthEast Community Bancorp Inc operates as a community-oriented financial institution. It is principally engaged in the business of attracting deposits and investing those funds into mortgage and commercial loans. It conducts activities throughout the Northeastern United States including New York, Massachusetts, New Jersey, and Connecticut. The company offers a comprehensive line of banking products and services, including mobile banking as well as commercial real estate loans, commercial construction financing, lines of credit, and term loans. It also offers investment advisory and financial planning services.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.